Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain

Trial Title: Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain

NCT ID: NCT06240390

Condition: Pain Cancer

Conditions: Official terms:
Analgesics, Opioid

Conditions: Keywords:
Cancer
Pain
Anterior Knee Pain
NMP

Study type: Interventional

Study phase: N/A

Overall status: Not yet recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: Triple (Care Provider, Investigator, Outcomes Assessor)

Masking description: Simple Blind, Evaluator

Intervention:

Intervention type: Device
Intervention name: Ultrasound-guided percutaneous neuromodulation (NMP)
Description: Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as transcranial direct current stimulation. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies. The Epte® Bipolar System device has an CE Health Certificate
Arm group label: Epte Bipolar System 2.0 - Ultrasound-guided percutaneous neuromodulation (NMP)

Intervention type: Drug
Intervention name: pharmacological treatment by Opioids
Description: Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.
Arm group label: pharmacological treatment by Opioids

Other name: pharmacological treatment - Opioids

Summary: the goal of this clinical trial is to compare in cancer patients: Is ultrasound-guided percutaneous neuromodulation useful for Anterior Knee Pain relief in cancer patients? Participants will receive treatments of ultrasound-guided percutaneous neuromodulation and pharmacological treatment Researchers will compare ultrasound-guided percutaneous neuromodulation versus pharmacological treatment to see if Anterior Knee Pain is reduced

Detailed description: Unhealthy lifestyles, an aging population and increased life expectancy increase the likelihood of cancer. Knee pain is one of the most common symptoms that cause functional incapacity, which requires the search and improvement of its assessment, prevention and treatment tools. Physiotherapists are currently using ultrasound-guided Percutaneous Neuromodulation clinically. It is an easy process to perform, non-invasive, safe and economical. Traditional therapies have been and will continue to be useful. The decrease in manufacturing costs of assessment tools such as ultrasound and neuromodulator treatment in recent years has made the acquisition of these equipment as intervention tools economical. This is because they have been shown to be useful for improving function and reducing pain. Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects. In order to improve these symptoms, it is essential to have an objective knowledge of the changes produced by neuromodulation and to be able to measure the variation of pain experienced by patients. It has been demonstrated in recent years that assessment tools such as ultrasound and myotonometer are very useful, safe and non-invasive procedures, both have been consolidated as assessment tools that can evaluate changes and analyze the contractile properties of soft tissue quickly and safely. There are abundant literature on this subject. Therefore, researchers suggest conducting research that improves and provides new data on the efficacy and effectiveness of treatment of ultrasound-guided percutaneous neuromodulation.

Criteria for eligibility:
Criteria:
Inclusion Criteria: The proposed inclusion criteria for the study are as follows: - Age between 18 and 65. - Pain in the front of the knee. - Taking drug therapy for lower-extremity pain. - Diagnosis of painful pathology in the anterior aspect of the knee secondary oncologic. Exclusion Criteria: The exclusion criteria are: - Traumatic history - Have had any type of analgesic treatment in the last 4 weeks (clinical, physical or orthostatic) - No need for drug treatment within the last 30 days of study initiation.

Gender: All

Minimum age: 18 Years

Maximum age: 65 Years

Healthy volunteers: No

Locations:

Facility:
Name: Centro RED Tenerife

Address:
City: Santa Cruz De Tenerife
Zip: 38002
Country: Spain

Start date: May 1, 2024

Completion date: December 1, 2024

Lead sponsor:
Agency: Universidad Europea de Canarias
Agency class: Other

Source: Universidad Europea de Canarias

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06240390